Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naveglitazar Phase 2 in Type 2 Diabetes
NCT00065312Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of naveglitazar in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Primary endpoint: Hemoglobin A1c. Status: completed.
02
Drugs
naveglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00065312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00065312.